Market›Health Care›Pharmaceuticals›Pharmaceuticals
Shionogi & Co. Ltd.

SGIOF

$19.10Apr 30, 2021 – Apr 29, 2026
Health CarePharmaceuticals$16.25B
MVM
+$16.25B
BLE
0.120
PositiveNegativeNo data· Dot size = magnitude · Scroll to zoom · Drag to pan
Chart Start
$17.72
2021
Since 2021
+7.8%
vs SPY +70.5%
All-time High
$45.50 · Oct 2024
-58.0% from peak
MVM Rank
#3 of 311
Pharmaceuticals
Reaction Win Rate
45%
18 of 40 events

Shionogi & Co. Ltd. has returned +7.8% from $17.72 since 2021, trailing SPY's +70.5% over the same period. The stock hit an all-time high of $45.50 in Oct 2024 and is currently 58.0% below that level. Of 40 tracked news events, 45% produced a positive market-adjusted return.

How to use this page
1Company Research Snapshot

Expand to read Wikipedia-sourced background on the company. Click any linked term to explore it inline — no page reload.

2Company Q&A

Common questions answered from real data: performance vs SPY, market cap, profitability, CEO, dividends, and more.

3News & Events

Every dot on the chart is a news event. The return shown is market-adjusted (vs SPY). Green = stock outperformed. Red = underperformed. Dot size = magnitude of reaction.

Show ▼
Company Q&AShow ▼
Hover to inspect

Want the full written briefing?

The chart shows what moved — the briefing shows why. Sourced, dated, no hot takes.

Subscribe on Substack →

News Events

DateReturnCategorySourceHeadline
2026-01-30+22.5%earningsThe Globe and MailShionogi Delivers Double-Digit Profit Growth and Confirms FY2026 Outlook - The Globe and Mail
2026-04-07+10.5%newsBusiness WireESCMID Global 2026: Shionogi Presents New Real-World Data Highlighting Clinical Effectiveness of Fetroja®/Fetcroja® (cefiderocol) in MBL-Producing Enterobacterales Infections
2026-04-08-6.6%expansionBusiness WireShionogi Receives Contract with U.S. Government Through BARDA's Project BioShield to Enhance National Preparedness for Drug-Resistant Bacterial Threats
2025-07-29-4.2%earningsSeeking AlphaShionogi & Co., Ltd. 2025 Q1 - Results - Earnings Call Presentation
2026-04-09-4.0%expansionPharmaceutical TechnologyShionogi secures $482m BARDA contract to tackle AMR crisis
2022-12-13+3.5%newsSeeking AlphaShionogi to deliver additional 1M courses of COVID pills to Japan
2024-03-06+3.4%analystSeeking AlphaViiVs long-acting HIV therapy outperforms daily therapy in Phase 3 trial
2026-03-26-3.2%newsYahoo FinanceSGIOY vs. SDZNY: Which Stock Is the Better Value Option? - Yahoo Finance
2023-11-01-3.0%earningsSeeking AlphaShionogi & Co., Ltd. (SGIOF) Q2 2023 Earnings Conference Call Transcript
2023-05-11-2.5%earningsSeeking AlphaShionogi & Co. GAAP EPS of 621.31, revenue of 426.7B
2024-07-23+2.4%newsSeeking AlphaViiV's Dovato as effective as Gilead's Biktarvy for HIV but with less weight gain
2026-04-13-2.2%expansionSimply Wall St.Shionogi’s Fetroja Contract And Data Shift U.S. Growth And Valuation Outlook
2026-04-14-2.0%executiveYahoo Finance VideoD-Wave CEO on quantum computing's ChatGPT moment, Nvidia, & more
2023-08-01+1.7%newsSeeking AlphaDaiichi COVID vaccine endorsed in Japan; Shionogis shot declined
2023-08-01+1.7%earningsSeeking AlphaShionogi & Co., Ltd. (SGIOF) Q1 2023 Earnings Call Transcript
2025-07-28-1.3%earningsSeeking AlphaShionogi & Co. reports Q1 results
2025-05-07-1.1%M&ASeeking AlphaShionogi to buy Japan Tobaccos Torii Pharma in a deal worth over $1B
2026-04-10-0.9%expansionBusiness WireThe Time to Talk about HIV is Now: ViiV Healthcare Launches "Still Here" PSA to Ignite Action Around HIV on National Youth HIV/AIDS Awareness Day
2026-04-10-0.9%newsBioPharma DiveRFK Jr. rewrites ACIP rules; Gilead, Roche dig into protein degraders
2026-01-20+0.9%newsSeeking AlphaPfizer exits GSK majority-owned ViiV Healthcare; Shionogi raises stake
2026-01-20+0.9%newsSeeking AlphaPfizer exits GSK majority-owned ViiV Healthcare; Shionogi raises stake - Seeking Alpha
2026-04-01-0.8%M&ABusiness WireShionogi Completes Acquisition of All Rights to RADICAVA (edaravone)
2026-04-01-0.8%newsPR NewswireTanabe Pharma America Announces Finalization of RADICAVA (edaravone) Transfer to Shionogi
2026-04-01-0.8%newsMT NewswiresSector Update: Health Care Stocks Advance Pre-Bell Wednesday
2023-07-24-0.7%newsSeeking AlphaGSK announces EU nod for HIV prevention therapy
2025-02-01+0.7%earningsSeeking AlphaShionogi & Co., Ltd. 2024 Q3 - Results - Earnings Call Presentation
2025-02-01+0.7%earningsSeeking AlphaShionogi targets JPY550B revenue through QOL focus and global expansion
2023-01-30-0.6%earningsSeeking AlphaShionogi & Co., Ltd. (SGIOF) Q3 2022 Earnings Call Transcript
2023-01-30-0.6%earningsSeeking AlphaShionogi & Co., Ltd. 2022 Q3 - Results - Earnings Call Presentation
2023-02-06-0.5%earningsSeeking AlphaShionogi & Co. reports Q3 results
2023-07-31+0.4%earningsSeeking AlphaShionogi & Co. GAAP EPS of 144.57, revenue of 109.31B
2022-12-16+0.4%newsSeeking AlphaViiV wins EU backing for new HIV drug formulation for children
2022-12-16+0.4%newsSeeking AlphaShionogi's Xocova Potentially Better Than Pfizer And Merck's Antivirals
2024-01-31+0.3%earningsSeeking AlphaShionogi & Co., Ltd. 2023 Q3 - Results - Earnings Call Presentation
2023-05-15+0.3%earningsSeeking AlphaShionogi & Co., Ltd. (SGIOF) Q1 2023 Earnings Call Transcript
2025-03-11+0.3%newsSeeking AlphaViiV releases promising phase 2 data on potential long-acting HIV drugs
2026-03-24-0.2%M&AThe Globe and MailShionogi Secures ¥360 Billion Bridge Loan to Fund Global RADICAVA Rights Deal - The Globe and Mail
2023-05-12-0.2%earningsSeeking AlphaShionogi & Co., Ltd. 2022 Q4 - Results - Earnings Call Presentation
2023-03-04-0.1%newsSeeking AlphaShionogi: Likely The Last Viable COVID Play
2023-02-27+0.0%executiveSeeking AlphaShionogi CEO sees $2B in sales of COVID pill following US approval - Reuters
tickerdossier.comtickerdossier.substack.com